Bank of New York Mellon Corp Sells 4,204 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Bank of New York Mellon Corp decreased its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 1.0% during the 4th quarter, HoldingsChannel reports. The fund owned 420,231 shares of the biopharmaceutical company’s stock after selling 4,204 shares during the quarter. Bank of New York Mellon Corp’s holdings in Ocular Therapeutix were worth $3,589,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Deltec Asset Management LLC increased its position in shares of Ocular Therapeutix by 0.6% during the 4th quarter. Deltec Asset Management LLC now owns 2,616,373 shares of the biopharmaceutical company’s stock worth $22,344,000 after purchasing an additional 16,300 shares during the last quarter. Braidwell LP increased its holdings in shares of Ocular Therapeutix by 36.3% during the 3rd quarter. Braidwell LP now owns 2,239,770 shares of the biopharmaceutical company’s stock worth $19,486,000 after acquiring an additional 596,000 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Ocular Therapeutix by 146.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,110,460 shares of the biopharmaceutical company’s stock worth $9,661,000 after acquiring an additional 660,080 shares during the last quarter. Knoll Capital Management LLC increased its holdings in shares of Ocular Therapeutix by 199.6% during the 3rd quarter. Knoll Capital Management LLC now owns 600,400 shares of the biopharmaceutical company’s stock worth $5,223,000 after acquiring an additional 400,000 shares during the last quarter. Finally, Barclays PLC increased its holdings in shares of Ocular Therapeutix by 37.1% during the 3rd quarter. Barclays PLC now owns 511,522 shares of the biopharmaceutical company’s stock worth $4,451,000 after acquiring an additional 138,441 shares during the last quarter. Institutional investors own 59.21% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Ocular Therapeutix in a report on Tuesday, March 4th. Royal Bank of Canada started coverage on Ocular Therapeutix in a research report on Tuesday. They set an “outperform” rating and a $17.00 target price for the company. Needham & Company LLC started coverage on Ocular Therapeutix in a research report on Tuesday, March 11th. They set a “buy” rating and a $15.00 price objective for the company. Finally, JMP Securities set a $19.00 price objective on Ocular Therapeutix in a research report on Tuesday, March 4th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, Ocular Therapeutix currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.38.

Insider Activity

In other news, insider Pravin Dugel sold 21,475 shares of Ocular Therapeutix stock in a transaction on Monday, February 24th. The stock was sold at an average price of $6.87, for a total value of $147,533.25. Following the completion of the transaction, the insider now directly owns 3,520,318 shares in the company, valued at approximately $24,184,584.66. The trade was a 0.61 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Donald Notman sold 6,301 shares of Ocular Therapeutix stock in a transaction on Friday, January 31st. The shares were sold at an average price of $7.84, for a total value of $49,399.84. Following the sale, the insider now directly owns 204,563 shares of the company’s stock, valued at $1,603,773.92. This represents a 2.99 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 38,895 shares of company stock worth $283,772 over the last 90 days. 3.50% of the stock is currently owned by corporate insiders.

Ocular Therapeutix Trading Up 3.4 %

NASDAQ OCUL opened at $7.70 on Thursday. The business has a 50 day simple moving average of $7.61 and a 200 day simple moving average of $8.80. Ocular Therapeutix, Inc. has a one year low of $4.06 and a one year high of $11.78. The stock has a market capitalization of $1.22 billion, a P/E ratio of -5.83 and a beta of 1.34. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94.

Ocular Therapeutix (NASDAQ:OCUL) last announced its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.05). Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. The firm had revenue of $17.08 million during the quarter, compared to the consensus estimate of $16.89 million. Research analysts expect that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current year.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.